Austin Hospital

Running trials

• Not yet recruiting

  Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study

  NCT07908147· Early phase 1· Source

• Not yet recruiting

  Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT07634289· Phase 2· Source

• Not yet recruiting

  Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma

  NCT07712770· Early phase 1· Source

• Recruiting

  Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy

  NCT07640191· Source

• Recruiting

  Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

  NCT07287202· Phase 1/2· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

  NCT07567846· Phase 1/2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Source

• Recruiting

  A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

  NCT06932562· Phase 3· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· Phase 2· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

  NCT07149857· Phase 2· Source

• Recruiting

  IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

  NCT07138222· Source

• Recruiting

  Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06896916· Phase 1· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

  NCT07202078· Phase 2/3· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

  NCT07202091· Phase 2/3· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

  NCT07202052· Phase 2/3· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

  NCT07202065· Phase 2/3· Source

• Enrolling by invitation

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

  NCT06908226· Phase 3· Source

• Active, not recruiting

  A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

  NCT06456463· Phase 2· Source

• Recruiting

  Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

  NCT06613009· Phase 1· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Source

• Active, not recruiting

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

  NCT06719141· Phase 3· Source

• Recruiting

  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  NCT06561048· Phase 3· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Source

• Active, not recruiting

  A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

  NCT06660394· Phase 3· Source

• Active, not recruiting

  A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

  NCT06550895· Phase 2· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Source

• Not yet recruiting

  Australasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke

  NCT06495671· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Source

• Recruiting

  Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke

  NCT05892510· Phase 2/3· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· Source

• Active, not recruiting

  Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation

  NCT05899985· Source

• Active, not recruiting

  T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

  NCT06157541· Phase 1/2· Source

• Recruiting

  Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

  NCT05658497· Source

• Active, not recruiting

  A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05257083· Phase 3· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Source

• Active, not recruiting

  Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)

  NCT07579390· Source

• Recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

  NCT05800665· Phase 1· Source

• Recruiting

  Alleviant ALLAY-HF Study

  NCT05685303· Source

• Active, not recruiting

  Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

  NCT05556720· Phase 3· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

  NCT05678621· Phase 2/3· Source

• Recruiting

  Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

  NCT05180097· Phase 2· Source

• Recruiting

  Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy

  NCT05169177· Source

• Recruiting

  Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

  NCT05533697· Phase 1/2· Source

• Recruiting

  Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

  NCT05254171· Phase 2/3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382286· Phase 3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382299· Phase 3· Source

• Active, not recruiting

  HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

  NCT05338970· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma10 recruiting
• Stroke4 recruiting
• Colorectal cancer3 recruiting
• Epilepsy2 recruiting
• Glioblastoma2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lung cancer2 recruiting
• Melanoma2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Multiple sclerosis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Source

• Completed

  A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke

  NCT06987643· Phase 2· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Completed

  Cough Reduction in IPF With Nalbuphine ER

  NCT05964335· Phase 2· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Completed

  A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

  NCT05452239· Phase 4· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Source

• Completed

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· Phase 3· Source

• Completed

  A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT04540796· Phase 1· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

  NCT04242199· Phase 1· Source

• Terminated

  A Phase 1 Study of [225Ac]-FPI-1434 Injection

  NCT03746431· Phase 1· Source

• Completed

  Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

  NCT03674567· Phase 1/2· Source

• Terminated

  A Study of Soticlestat in Adults and Children With Rare Epilepsies

  NCT03635073· Phase 2· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Source

• Completed

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· Phase 3· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Source

• Recruiting

  Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

  NCT03588286· Source

Trial sites

• Austin Hospital65 trials
• Austin Hospital2 trials
• Austin Hospital18 trials
• Austin Hospital /ID# 2659841 trial
• Austin Hospital /ID# 2765341 trial
• The Austin Hospital3 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Primary biliary cholangitis4 works · 0 trials
• Follicular lymphoma4 works · 0 trials
• Polycystic kidney disease3 works · 0 trials